NantKwest Announces Durable Complete Responses in Multiple Advanced-Stage Solid Tumor Cancers Following Off-the-Shelf NK Cell...
June 04 2019 - 8:00AM
Business Wire
5 out of 35 Durable Complete Responses
Observed in Patients with Relapsed Third-Line Advanced Solid Tumors
with Duration Ranging 4 to 24 Months
Patrick Soon-Shiong, MD, Chairman and CEO of NantKwest
(Nasdaq:NK), a leading clinical-stage, natural killer cell based
therapeutics company today presented a clinical data update in
patients who have received off-the-shelf aNK and/or haNK natural
killer cell therapy in combination with immunotherapeutic agents in
advanced solid tumors. These results demonstrated durable complete
responses in 5 out of 35 patients with highly refractory late stage
cancers across multiple tumor types.
Data presented at the Jefferies Healthcare Conference
demonstrated complete responses across phase I combination studies
of aNK/haNK with or without N-803, ImmunityBio, Inc.’s IL-15 fusion
superagonist in solid tumor cancer patients with highly refractory
disease. ImmunityBio, Inc. (formerly known as NantCell, Inc.) is an
affiliated company of NantKwest. These combinations enhance NK and
T cell activity and proliferation, and resulted in 14% complete
responses across multiple indications, while demonstrating positive
safety profiles. In patients with highly refractory and relapsed
diseases who have failed multiple rounds of standard-of-care
therapy, the responses were durable.
All five patients with complete responses remain alive to date,
ranging from 4 to 24 months from the onset of response.
“We are excited by the durable complete responses seen in
patients with highly refractory disease safely treated with
off-the-shelf haNK or aNK -- to date over 511 infusions of haNK
cell therapy have been administered, without any patient requiring
hospitalization or resulting in cytokine release syndrome,” said
Patrick Soon-Shiong, M.D. “These early signals of efficacy have now
provided us a pathway to the development of registration trials
across triple negative breast cell and Merkel cell carcinoma.”
In addition, Dr. Soon-Shiong also announced the FDA
authorization of a trial utilizing the first in class CD19 T-haNK
for treatment of refractory diffuse large B-Cell Lymphoma and the
IND filing of the first in class PD-L1 T-haNK for refractory solid
tumors.
For additional information please go
to www.nantkwest.com.
About NantKwest
NantKwest, a member of the NantWorks ecosystem of companies, is
an innovative clinical-stage immunotherapy company focused on
harnessing the power of the innate immune system by using the
natural killer cell to treat cancer and virally induced infectious
diseases.
NantKwest is uniquely positioned to implement precision cancer
medicine, with the potential to change the current paradigm of
cancer care. Natural Killer (NK) cells are a safeguard in the human
body designed to recognize and detect cells under stress due to
cancer or viral infection. NantKwest’s “off-the-shelf” activated NK
cell platform is designed to destroy cancer and virally infected
cells from the body. The safety of our NK cells as well as their
activity against a broad range of cancers have been tested in phase
I clinical trials in Canada and Europe as well as in multiple phase
I and II clinical trials in the United States. In addition to being
a universal cell-based therapy that does not require individualized
patient sourcing or matching, our NK cell products have been
largely administered in the outpatient setting as an
“off-the-shelf” living drug.
With the capacity to grow active killer cells as a cancer
therapy, our NK cells have been designed to induce cell death
against cancers and virally infected cells by several mechanisms,
including: (i) innate killing, whereby all of our NK platforms
recognize the stress proteins typically found on cancer cells,
which, upon binding, release toxic granules to immediately kill
their targets; (ii) antibody-mediated killing with our haNK®
platform, which are NK cells engineered to express antibody
receptors that can bind to therapeutic antibody products, thereby
enhancing the cancer cell killing effect of that antibody; and
(iii) Chimeric Antigen Receptor directed killing using the taNK®
platform, which includes NK cells engineered to incorporate
chimeric antigen receptors (CARs) to target tumor-specific antigens
found on the surface of cancer cells. All three modes of killing
(innate, antibody-mediated, and CAR directed killing) are employed
by our t-haNK™ platform, which is an innovative combination of our
aNK, haNK® and taNK® platforms in a single product.
Our haNK®, and t-haNK™ platforms have been designed to address
certain limitations of CAR T-cell therapy including the capability
to infuse cell therapy in an outpatient setting which allows for
potential reduction of risk for serious cytokine storms and
protracted serious adverse events. In phase I and II clinical
trials in patients with late stage cancer, our NK cells have been
administered as an investigational outpatient infusion safely with
greater than 500 infusions to date at a dose of 2 billion cells per
infusion.
By leveraging an integrated and extensive genomics and
transcriptomics discovery and development engine, together with a
pipeline of multiple, clinical-stage, immuno-oncology programs, we
believe NantKwest is uniquely positioned to be the premier
immunotherapy company and transform medicine by delivering living
drugs in a bag and bringing novel NK cell-based therapies to
routine clinical care.
NK-92, aNK, haNK, taNK, and t-haNK are trademarks of NantKwest,
Inc.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements include statements concerning or
implying that NantKwest will be successful in improving the
treatment of cancer. Risks and uncertainties related to this
endeavor include, but are not limited to, obtaining FDA approval of
NantKwest’s NK cells as well as other therapeutics as part of the
NANT Cancer Vaccine platform as a cancer treatment.
Forward-looking statements are based on management's current
expectations and are subject to various risks and uncertainties
that could cause actual results to differ materially and adversely
from those expressed or implied by such forward-looking statements.
Accordingly, these forward-looking statements do not constitute
guarantees of future performance, and you are cautioned not to
place undue reliance on these forward-looking statements.
These and other risks regarding NantKwest’s business are
described in detail in its Securities and Exchange Commission
filings, including in NantKwest’s Quarterly Report on Form 10-Q for
the quarter ended March 31, 2019. These forward-looking statements
speak only as of the date hereof, and we disclaim any obligation to
update these statements except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190604005450/en/
Jen HodsonNANT562-397-3639Jen@nant.com
NantKwest (NASDAQ:NK)
Historical Stock Chart
From Apr 2024 to May 2024
NantKwest (NASDAQ:NK)
Historical Stock Chart
From May 2023 to May 2024